Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer.

Peters S, Meylan E.

Curr Opin Oncol. 2013 Mar;25(2):137-44. doi: 10.1097/CCO.0b013e32835d720b. Review.

PMID:
23283210
2.

Bone metastases and non-small cell lung cancer: from bisphosphonates to targeted therapy.

Rossi A, Gridelli C, Ricciardi S, de Marinis F.

Curr Med Chem. 2012;19(32):5524-35. Review.

PMID:
22963665
3.

RANKL inhibition in the treatment of bone metastases.

Lipton A, Jun S.

Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. doi: 10.1097/SPC.0b013e32830baac2. Review.

PMID:
18685421
4.

Denosumab: the era of targeted therapies in bone metastatic diseases.

Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G.

Curr Cancer Drug Targets. 2009 Nov;9(7):834-42. Review.

PMID:
20025571
5.

The role of RANK-ligand inhibition in cancer: the story of denosumab.

Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H.

Oncologist. 2011;16(2):136-45. doi: 10.1634/theoncologist.2010-0154. Epub 2011 Feb 1. Review.

6.

RANKL signaling in bone physiology and cancer.

Dougall WC.

Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Review.

PMID:
18685382
8.

Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.

Saad F, Markus R, Goessl C.

BJU Int. 2008 May;101(9):1071-5. Epub 2007 Dec 5. Review.

9.

Denosumab for the management of bone disease in patients with solid tumors.

Body JJ.

Expert Rev Anticancer Ther. 2012 Mar;12(3):307-22. doi: 10.1586/era.11.204. Epub 2011 Dec 22. Review.

PMID:
22192269
10.
11.

[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1343-6. Chinese.

12.

[Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].

Yoneda T.

Clin Calcium. 2011 Aug;21(8):1159-66. doi: CliCa110811591166. Review. Japanese.

PMID:
21814020
13.

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.

Dougall WC.

Clin Cancer Res. 2012 Jan 15;18(2):326-35. doi: 10.1158/1078-0432.CCR-10-2507. Epub 2011 Oct 26.

14.

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ.

Clin Cancer Res. 2006 Feb 15;12(4):1221-8.

15.

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.

Bone. 2007 Apr;40(4):981-90. Epub 2006 Dec 28.

PMID:
17196895
16.

Implications of bone metastases and the benefits of bone-targeted therapy.

Lipton A.

Semin Oncol. 2010 Oct;37 Suppl 2:S15-29. doi: 10.1053/j.seminoncol.2010.10.002. Review.

PMID:
21111244
17.
18.

[Bone metastasis in prostate cancer].

Moltzahn F, Thalmann GN.

Urologe A. 2012 Jan;51(1):20-6. doi: 10.1007/s00120-011-2741-1. German.

PMID:
22258372
20.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
Items per page

Supplemental Content

Write to the Help Desk